At the time of writing, the Recce share price is down 1.85% to $1.06 per share.
Recce is a drug discovery and development business commercialising a new class of synthetic antibiotics with a broad-spectrum activity designed to address the global health challenge of antibiotic-resistant superbugs.
Its patented lead drug candidate is a synthetic anti-infective, which has been developed to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms.
Recce’s quarterly performance and cash flow
The Recce share price is down today despite a reasonably…
Health24 hours ago
Covid-19 vaccines do not increase the risk of miscarriage – The Times Hub
Business22 hours ago
First Time In A Decade: Qantas Plans Direct A330 India Flights – Simple Flying
Health19 hours ago
South Korea hits key COVID-19 vax target – The West Australian
Science16 hours ago
Scientists want you to help them discover new planets, here`s how – WION